How long do Cosentyx (secukinumab) benefits typically last after starting treatment?
Cosentyx is designed to provide ongoing control of inflammatory disease. In practice, patients are usually kept on treatment long term because the benefits are tied to continued dosing rather than a one-time effect [1].
For psoriasis and psoriatic arthritis, studies and prescribing information support sustained benefit over extended treatment periods when the drug is continued [1][2].
How quickly do patients usually notice benefits, and does the effect wear off?
Patients often report improvement within the first weeks to a couple of months, but the exact timeline varies by condition and individual response. If treatment is stopped, the underlying inflammatory disease typically becomes active again, which means the benefits usually do not last indefinitely without ongoing therapy [1].
Do benefits last as long as long-term dosing continues?
Yes. The goal with Cosentyx is durable symptom control with continued injections. Long-term evidence in clinical studies shows maintenance of responses for patients who stay on therapy [1][2].
What about different conditions (psoriasis vs psoriatic arthritis vs ankylosing spondylitis)?
The durability of benefit is generally similar in concept—patients maintain control with continued dosing—but the level and timing of response can differ by disease type. Cosentyx is used across several inflammatory indications, and each has its own clinical study results and monitoring approach [1][2].
If a patient misses doses or stops Cosentyx, what happens to benefits?
Because Cosentyx works by suppressing the inflammatory pathways driving symptoms, missing doses or stopping treatment typically leads to loss of disease control over time in many patients. That pattern is why continued maintenance dosing is part of the prescribing approach [1].
Sources
- https://www.cosentyx.com/patient/what-is-cosentyx/how-it-works
- https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx